| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CLEC4A; DCIR; LLIR; DDB27; CLECSF6; HDCGC13P |
| Entrez GeneID | 50856 |
| clone | 1B4A10 |
| WB Predicted band size | 27.5kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD367 (AA: extra 70-237) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD367(TIM-3)抗体的3篇代表性文献及其摘要内容的简要总结：
---
1. **文献名称**: *TIM-3 regulates CD8+ T cell exhaustion and PD-1 blockade efficacy in chronic viral infection*
**作者**: Jin HT 等
**摘要**: 研究揭示了TIM-3(CD367)在慢性病毒感染中通过抑制T细胞功能介导免疫耗竭的机制，并证明阻断TIM-3抗体可逆转T细胞耗竭，增强抗病毒免疫反应，与PD-1阻断具有协同治疗效果。
---
2. **文献名称**: *Anti-TIM-3 Antibody Promotes T Cell IFN-γ-Mediated Antitumor Immunity and Suppresses Established Tumors*
**作者**: Zhou Q 等
**摘要**: 该研究通过临床前模型证明，抗TIM-3抗体通过激活CD8+ T细胞分泌IFN-γ，显著抑制肿瘤生长，并增强现有化疗药物的疗效，提示TIM-3抗体在实体瘤治疗中的潜力。
---
3. **文献名称**: *TIM-3 Expression on Tumor Cells Predicts Resistance to Anti-PD-1 Therapy*
**作者**: Anderson AC 等
**摘要**: 文章发现肿瘤微环境中TIM-3的高表达与PD-1抗体治疗耐药性相关，联合使用抗TIM-3和抗PD-1抗体可显著恢复T细胞活性，为克服免疫治疗耐药性提供了新策略。
---
4. **文献名称**: *Targeting TIM-3 in Cancer: Rationale and Preclinical Evidence*
**作者**: Wolf Y 等
**摘要**: 综述总结了TIM-3在肿瘤免疫逃逸中的作用，强调抗TIM-3抗体通过调节树突状细胞和T细胞功能增强抗肿瘤免疫应答，并讨论了其在临床试验中的进展。
---
以上文献均聚焦于TIM-3(CD367)抗体在调节免疫应答、增强肿瘤治疗及联合疗法中的应用机制。如需具体文献来源，可进一步通过PubMed或期刊官网检索标题及作者。
CD367. also known as Clec9A or DNGR-1. is a C-type lectin receptor predominantly expressed on a subset of dendritic cells (DCs), particularly conventional type 1 DCs (cDC1s). Discovered in the early 2000s, it recognizes filamentous actin (F-actin) exposed on necrotic cells, serving as a damage-associated molecular pattern (DAMP) sensor. Structurally, it features a conserved carbohydrate-recognition domain (CRD) critical for ligand binding and a cytoplasmic signaling motif that mediates antigen cross-presentation, a key process in cytotoxic T-cell activation.
CD367 antibodies are valuable tools for studying DC biology and immune responses. They can block Clec9A-F-actin interactions or act as targeting agents to deliver antigens to cDC1s, enhancing vaccine efficacy. For example, anti-Clec9A conjugates have been explored in preclinical cancer immunotherapies and antiviral vaccines to promote robust antigen-specific immunity. Additionally, CD367 antibodies help identify cDC1 subsets in tissues, aiding research on their roles in infection, autoimmunity, and tumor immunity. Their specificity and functional versatility make them pivotal in advancing DC-targeted therapeutic strategies.
×
